Assertio, Hanmi amend ROLVEDON supply agreement; price cut mid-single digits

Assertio Holdings, Inc.

Mid-single-digit price reduction on ROLVEDON drug substance from Hanmi, fixed through license term.
Supplier may request price increases from 2028 if costs rise above threshold.
Per-gram pricing decreases if global ROLVEDON volume exceeds unmet threshold.
Spectrum must provide annual forecast; at least 50% of forecasted orders binding.
No minimum purchase requirements; Spectrum may negotiate lower price if process cuts costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.